Skip to main content
SpringerLink
Log in

CSF and serum total-tau and phospho-tau(181P) in MS patients

  • Research Article
  • Published:
Central European Journal of Medicine

Abstract

In search of biological marker in multiple sclerosis (MS), total-tau and phospho-tau (Thr181) concentrations were established in CSF and serum of 78 patients with MS, using commercially available kits. Serum and CSF concentrations of IgG, IgM, and albumin were assayed simultaneously to calculate quotients and indices of intrathecal synthesis. Serum t-tau detection was strikingly low (23.1%); therefore, this factor was excluded from further analysis. Serum p-tau levels did not correlate with any of indices or quotients. Unexpectedly, CSF t-tau and p-tau showed an inverse relation with MSSS and EDSS, which has not been published elsewhere. Our results do not support utility of serum t-tau and p-tau as surrogate markers for MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Stefano N., Matthews P. M., Fu L., Narayanan S., Stanley J., Francis G. S., Antel J. P. et al., Axonal damage correlates with disability in patients with repalsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study, Brain, 1998; 121, 1469–1477

    Article  PubMed  Google Scholar 

  2. Roxburgh R. H., Seaman S. R., Masterman T., Hensiek A. E., Sawcer S. J., Vukusic S. et al., Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity, Neurology, 2005, 64, 1144–1151

    CAS  PubMed  Google Scholar 

  3. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 1983, 33, 1444–1452

    CAS  PubMed  Google Scholar 

  4. Pachner A. R., Steiner I., The multiple sclerosis severity score (MSSS) predicts disease severity over time, J. Neurol. Sci., 2009, 278, 66–70

    Article  PubMed  Google Scholar 

  5. Weingarten M. D., Lockwood A. H., Hwo S-Y., Kirschner M. W., A protein factor essential for microtubule assembly, Proc. Nat. Acad. Sci. USA, 1975, 72, 1858–1862

    Article  CAS  PubMed  Google Scholar 

  6. Trojanowski J. Q., Schuck T., Schmidt M. L., Lee V. M., Distribution of tau proteins in the normal human central and peripheral nervous system, J. Histochem. Cytochem., 1989, 37, 209–215

    CAS  PubMed  Google Scholar 

  7. Avila J., Lucas J. J., Perez M., Hernandez F., Role of tau protein in both physiological and pathological processes. Physiol. Rev., 2004, 84, 361–384

    Article  CAS  PubMed  Google Scholar 

  8. Ibach B., Binder H., Dragon M., Poljansky S., Haen E., Schmitz E., et al., Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample, Neurobiol. Aging, 2006, 27, 1202–1211

    Article  CAS  PubMed  Google Scholar 

  9. Skinningsrud A., Stenset V., Gundersen A. S., Fladby T., Cerebrospinal fluid markers in Creutzfeldt-Jakob disease, Cer. Fluid. Res., 2008, 5, 1–8

    Article  Google Scholar 

  10. Süssmuth S. D., Reiber H., Tumani H., Tau protein in cerebrospinal fluid (CSF): a blood-CSF related evaluation in patients with various neurological disease, Neurosci. Lett., 2001, 300, 95–98

    Article  PubMed  Google Scholar 

  11. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E. et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett., 2001, 297, 187–190

    Article  CAS  PubMed  Google Scholar 

  12. Zelman F. P., Jauch E. C., Mulchahey J. J., Gabbita S. P., Rosenberg W. S., Speciale S. G.et al., C-tau biomarker of neuronal damage is severe brain injured patients: association with elevated intracranial pressure and clinical outocome, Brain Res., 2002, 947, 131–139

    Article  Google Scholar 

  13. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P. R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130

    Article  PubMed  Google Scholar 

  14. Hernández F., Pérez M., de Barreda E. G., Goñi-Oliver P., Avila J., Tau as a molecular marker of development, aging and neurodegenerative disorders, Curr. Aging Sci., 2008, 1: 56–61

    PubMed  Google Scholar 

  15. Hein (nee Maier) K., Köhler A., Diem R., Sättler M. B., Demmer I., Lange P. et al., Biological markers for axonal degeneration in CSF and blood of patients with first event indicative for multiple sclerosis, Neurosci. Lett., 2008, 436, 72–76

    Article  CAS  Google Scholar 

  16. Reiber H., Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics, Rest. Neurol. Neurosci., 2003, 21: 79–96

    CAS  Google Scholar 

  17. Polman C. H., Reingold S. C., Edan G., Fillipi M., Hartung H. P., Kappos L. et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“, Ann. Neurol., 2005, 58: 840–846

    Article  PubMed  Google Scholar 

  18. Reiber H., Peter J. B., Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs, J. Neurol. Sci., 2001, 184: 101–122

    Article  CAS  PubMed  Google Scholar 

  19. Jiménez-Jiménez F. J., Zurdo J. M., Hernanz A., Medina-Acebrón S., de Bustos F., Barcenilla B. et al., Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis, Acta Neurol. Scand., 2002, 106, 351–354

    Article  PubMed  Google Scholar 

  20. Guimarães J., Cardoso M. J., Sá M. J., Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis, Mult. Scler., 2006; 12, 354–356

    Article  PubMed  Google Scholar 

  21. Valis M., Talab R., Stourac P., Andrys C., Masopust J., Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients, Neuro. Endocrinol. Lett., 2008, 29, 971–976

    CAS  PubMed  Google Scholar 

  22. Kapaki E., Paraskevas G. P., Michalopoulou M., Kilidireas K., Increased cerebrispinal fluid tau protein in multiple sclerosis, Eur. Neurol., 2000, 43, 228–232

    Article  CAS  PubMed  Google Scholar 

  23. Terzi M., Birinci A., Çetinkaya E., Onar M. K., Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis, Acta Neurol. Scand., 2007, 115, 325–330

    Article  CAS  PubMed  Google Scholar 

  24. Brettschneider J., Maier M., Arda S., Claus A., Süssmuth S. D., Kassubek J. et al., Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, Mult. Scler., 2005, 11, 261–265

    Article  CAS  PubMed  Google Scholar 

  25. Rostazy K., Withhut E., Pohl D., Lange P., Cisielcyk B., Diem R. et al., Tau, phospho-tau and S-100B in cerebrospinal fluid of children with multiple sclerosis, J. Child. Neurol., 2005, 20, 822–825

    Article  Google Scholar 

  26. Teunissen C. E., Dijkstra C., Polman C., Biological markers in CSF and blood for axonal degeneration in multiple sclerosis, Lancet Neurol., 2005, 4, 32–41

    Article  PubMed  Google Scholar 

  27. Anderson J. M., Patani R., Reynolds R., Nicholas R., Compston A., Spillantini M. G. et al., Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis, Acta Neuropathol., 2009, 117, 583–589

    Article  CAS  PubMed  Google Scholar 

  28. Anderson J. M., Hampton D. W., Patani R., Pryce G., Crowther R. A., Reynolds R. et al., Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis, Brain, 2008, 131, 1736–48

    Article  CAS  PubMed  Google Scholar 

  29. Andersson M., Alvarez-Cermeño J., Bernardi G., Cogato I., Fredman P., Frederiksen J, Fredrikson S. et al., Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report, J. Neurol. Neurosurg. Psychiatry, 1994, 57, 897–902

    Article  CAS  PubMed  Google Scholar 

  30. Zemlan F. P., Rosenberg W. S., Luebbe P. A., Campbell T. A., Dean G. E., Weiner N. E. et al., Quantification od axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins, J. Neurochem., 1999, 72, 741–750

    Article  CAS  PubMed  Google Scholar 

  31. Ingelson M., Blomberg M., Benedikz E., Wahlund L-O., Karlsson E., Vanmechelen E. et al., Tau immunoreactivity detected in human plasma, but no obvious increase in dementia, Dement Geriatr Cogn Disord, 1999, 10, 442–445

    Article  CAS  PubMed  Google Scholar 

  32. Bakshi R., Dandamudi Venkata S. R., Neema M., De C., Bermel R. A., Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis, J Neuroimaging, 2005, 15, 30S–45S

    Article  PubMed  Google Scholar 

  33. Jasperse B., Jakobs C., Eikelenboom M. J., Dijkstra C. D., Uitdehaag B. M. J., Barkhoff F. et al., N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gaschromatography-mass spectrometry, J Neurol, 2007, 254, 631–637

    Article  CAS  PubMed  Google Scholar 

  34. Tenissen C. E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M. J. A. et al., Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis, Neurology, 2009, 72, 1322–1329

    Article  Google Scholar 

  35. Compston A., Lassmann H., Smith K., Differences between acute, relapsing and progressive multiple sclerosis, In: Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J. et al., McAlpine’s Multiple Sclerosis, 4th Ed., Churchill Livingstone Elsevier, Oxford, UK, 2005, 594–596

    Google Scholar 

  36. Ott B. R., Cohen R. A., Gongvatana A., Okonkwo O. C., Johanson C. E., Stopa E. G. et al., Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease, J Alzheimer Dis, 2010, 20, 647–657

    CAS  Google Scholar 

  37. Fagan A. M., Head D., Shah A. R., Marcus D., Mintun M., Morris J. C. et al., Decreased CSF Aβ42 correlates with brain atrophy in cognitively normal elderly, Ann Neurol, 2009, 65, 176–183

    Article  CAS  PubMed  Google Scholar 

  38. Tosun D., Schuff N., Truran-Sacrey D., Shaw L. M., Trojanowski J. Q., Aisen P. et al, Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal study, Neurobiol Aging, 2010, 31, 1340–1354

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Medical University of Lublin, 20-954, Lublin, Poland

    Jacek Jaworski & Halina Bartosik-Psujek

  2. 2nd Department of Anaesthesiology and Intensive Care, Medical University of Lublin, 20-081, Lublin, Poland

    Marek Psujek

Authors
  1. Jacek Jaworski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marek Psujek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Halina Bartosik-Psujek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacek Jaworski.

About this article

Cite this article

Jaworski, J., Psujek, M. & Bartosik-Psujek, H. CSF and serum total-tau and phospho-tau(181P) in MS patients. cent.eur.j.med 6, 193–200 (2011). https://doi.org/10.2478/s11536-011-0003-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2478/s11536-011-0003-7

Keywords

Search

Navigation